Study on best treatment for bleeding under the retina
Part of Eyes & vision clinical trials.
This trial looks at whether the type of abnormal blood vessels under the retina affects how well a procedure (pneumatic displacement) works to move a macular hemorrhage (bleeding) out of the central vision area. It may help doctors choose the best approach for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You are white (Caucasian)
- You have a recent bleeding under the retina (within 36 hours) caused by abnormal blood vessels (macular neovascularization)
- The bleeding is at least the size of a small finger tip and located in the central vision area
- You have not had this same procedure before in the affected eye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special low-level laser treatment (photobiomodulation) can help people with an early form of age-related macular degeneration called reticular pseudodrusen. It may slow vision loss or protect your eyes from getting worse.
This trial tests a new stem-cell treatment for people with advanced dry age-related macular degeneration (AMD), a condition that causes blurring or loss of central vision. It aims to replace damaged cells in the back of the eye to potentially slow vision loss and improve day-to-day sight.
This trial tests a refillable eye implant (PDS) that slowly releases medication to treat wet age-related macular degeneration (nAMD). It aims to see if replacing the implant every 36 weeks works as well as regular eye injections.
This trial tests whether a specific eye surgery plus targeted clot-busting medicine and gas can improve vision after bleeding under the retina from “wet” age-related macular degeneration. It aims to reduce how long the bleeding lasts and help protect the central vision.
This trial tests a new treatment for people with a specific type of age-related macular degeneration (AMD) that has not improved after standard anti-VEGF injections. The goal is to see if it can stop vision loss and reduce retinal damage.
This trial tests whether switching from anti-VEGF injections to a special laser is better than continuing injections alone for people with diabetic macular edema whose central retinal thickness has dropped below 400 microns after the first year of treatment.
Hear when a new AMD - Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.